Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IIA clinical trial assessing AL001 for treatment of Post-Traumatic Stress Disorder.

Next Previous
Trial Profile

Phase IIA clinical trial assessing AL001 for treatment of Post-Traumatic Stress Disorder.

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lithium cocrystal Alzamend Neuro (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Registrational; Therapeutic Use
  • Sponsors Alzamend Neuro

Most Recent Events

  • 16 Jun 2025 According to the Alzamend Neuro media release, the company announced $5 million in gross proceeds from this Financing received, The capital raised will be used to support the five Phase II clinical trials of AL001 "Lithium in Brain" Studies at Massachusetts General Hospital.
  • 07 May 2025 According to an Alzamend Neuro media release, the company announced its partnership with Mint Labs Inc. d/b/a QMENTA a leading medical imaging artificial intelligence company, to support its five upcoming Phase II clinical trials of AL001 at Massachusetts General Hospital.
  • 19 Aug 2024 According to Alzamend Neuro media release, the company is optimistic that this study will assist in meeting the regulatory safety standards through the Section 505(b)(2) pathway for approval by the U.S. Food and Drug Administration, which is specifically designed for new formulations/ delivery systems of an approved drug.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top